FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
Real-time Estimate Tradegate  -  04:59 2022-07-05 am EDT
47.49 EUR   -0.37%
01:23aBelgium's Fagron Buys Fresenius Kabi Outsourcing Plant in US
MT
07/04Fitch Confirms Rating, Outlook on Fresenius Medical Care
MT
07/04Fitch Affirms Fresenius Rating, Outlook on Portfolio Diversity
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
06/29/2022 06/30/2022 07/01/2022 07/04/2022 07/05/2022 Date
48.01(c) 47.63(c) 47.58(c) 47.66(c) 47.62 Last
694 850 922 356 610 101 466 826 50 590 Volume
+0.44% -0.79% -0.10% +0.17% -0.08% Change
More quotes
Estimated financial data (e)
Sales 2022 18 981 M 19 795 M 19 795 M
Net income 2022 976 M 1 018 M 1 018 M
Net Debt 2022 11 165 M 11 643 M 11 643 M
P/E ratio 2022 14,3x
Yield 2022 2,73%
Sales 2023 19 942 M 20 797 M 20 797 M
Net income 2023 1 242 M 1 295 M 1 295 M
Net Debt 2023 10 606 M 11 060 M 11 060 M
P/E ratio 2023 11,4x
Yield 2023 3,01%
Capitalization 13 966 M 14 564 M 14 564 M
EV / Sales 2022 1,32x
EV / Sales 2023 1,23x
Nbr of Employees 122 635
Free-Float 67,7%
More Financials
Company
Fresenius Medical Care AG & Co. KGaA is the world's leading supplier of services and equipment for patients with kidney problems. Net sales break down by activity as follows: - clinical care services (78.8%): operated, at the end of 2021, 4,171 institutions; - manufacturing of dialyzers and related products (21.2%): hemo-dialysis and pediatric dialysis machines, etc. The group also offers therapies accompanied by... 
More about the company
Ratings of Fresenius Medical Care AG & Co. KGaA
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A
More Ratings
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
01:23aBelgium's Fagron Buys Fresenius Kabi Outsourcing Plant in US
MT
07/04Fitch Confirms Rating, Outlook on Fresenius Medical Care
MT
07/04Fitch Affirms Fresenius Rating, Outlook on Portfolio Diversity
MT
07/04FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Buy rating from Jefferies
MD
06/27Jefferies Double Upgrades Fresenius Medical Care to Buy From Underperform
MT
06/27ANALYST RECOMMENDATIONS : Amazon, AutoZone, Lyondellbasell, WEC Energy, Coinbase...
06/27FMC FRESENIUS MEDICAL CARE AG & CO K : Upgraded by Jefferies
MD
06/23FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Buy rating from Berenberg
MD
06/23FMC FRESENIUS MEDICAL CARE AG & CO K : UBS maintains a Buy rating
MD
06/22FMC FRESENIUS MEDICAL CARE AG & CO K : Barclays reaffirms its Neutral rating
MD
06/22Truist Securities Adjusts Fresenius Medical Care's Price Target to $27 From $34, Keeps ..
MT
06/22FMC FRESENIUS MEDICAL CARE AG & CO K : JP Morgan keeps a Sell rating
MD
06/22FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Buy rating from UBS
MD
06/21U.S. Supreme Court rules against DaVita over dialysis coverage
RE
06/21FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Buy rating from Berenberg
MD
More news
News in other languages on FRESENIUS MEDICAL CARE AG & CO. KGAA
01:23aLa société belge Fagron rachète l'usine de sous-traitance de Fresenius Kabi aux États-U..
01:20aFagron breidt Amerikaanse steriele activiteiten uit
07/04Fitch confirme la note et les perspectives de Fresenius Medical Care
07/04Fitch confirme la note de Fresenius et la perspective de la diversité du portefeuille
06/29MÄRKTE EUROPA/Schwächer - 13.000er Marke im DAX hält
More news
Analyst Recommendations on FRESENIUS MEDICAL CARE AG & CO. KGAA
More recommendations
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 47,66 €
Average target price 65,28 €
Spread / Average Target 37,0%
EPS Revisions
Managers and Directors
Rice Powell Chief Executive Officer
Helen Giza Chief Financial & Transformation Officer
Dieter Schenk Chairman-Supervisory Board
Franklin W. Maddux Executive VP-Clinical & Scientific Affairs
Rolf Allan Classon Vice Chairman-Supervisory Board
Sector and Competitors